Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Dr. Barbara Weber’s employment with Tango Therapeutics, Inc. (the “ Company”) as its Executive Chair ended on August 3, 2026 in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026 (the “ Employment Agreement”). Consistent with the terms of the Employment Agreement, Dr. Weber is deemed to have resigned from all officer and board member positions, including as a member of Company’s board of directors (the “ Board”) upon the termination of Dr. Weber’s employment. Dr. Weber’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies. In connection with Dr. Weber’s separation and consistent with the Employment Agreement, the Company offered Dr. Weber the opportunity to receive: (i) severance pay at Dr. Weber’s current base salary through December 31, 2026, paid out in substantially equal installments, and (ii) reimbursement for any monthly COBRA premium payments up to December 31, 2026 and (ii) acceleration of the vesting of such number of Dr. Weber’s outstanding option and restricted stock unit awards that would have otherwise vested had Dr. Weber remained in continuation of her service with the Company for an additional twelve months following August 3, 2026. In addition, the Company has offered to extend the post-termination exercise period for any of Dr. Weber’s vested stock options as of August 3, 2026, along with the options subject to the acceleration of vesting as described above, to the earlier of August 3, 2027 or the original expiration date of the applicable option and to pay Dr. Weber a pro-rata portion of the annual incentive compensation that she would otherwise be entitled to receive, if any, based on Company and individual performance for 2026, which will be paid at the same time as annual incentive compensation payments are made to the Company’s active employees for 2026, no later than March 15, 2027. In order to receive the foregoing benefits, Dr. Weber must execute and not revoke a Separation Agreement as set forth in the Employment Agreement. The foregoing description of the terms and conditions of the Separation Agreement does not purport to be complete and is qualified in its entirety by the Separation Agreement, which will be filed by the Company once it has become fully effective.